PADCEV plus Keytruda reduces bladder cancer recurrence risk by 47%
Go back to PADCEV plus Keytruda reduces bladder cancer recurrence risk by 47%| Astellas Pharma Inc Unsponsored ADR (AMEX: ALPMY) | Delayed: 13.34 +0.19 (1.44%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $13.15 | 52 Week High | $19.40 | |||
| Open | $13.03 | 52 Week Low | $12.50 | |||
| Day High | $13.37 | P/E | N/A | |||
| Day Low | $13.03 | EPS | $0.00 | |||
| Volume | 198,689 | |||||
| Pfizer Inc. (NYSE: PFE) | Delayed: 24.29 +0.62 (2.62%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $23.67 | 52 Week High | $37.39 | |||
| Open | $23.74 | 52 Week Low | $28.25 | |||
| Day High | $24.35 | P/E | 14.72 | |||
| Day Low | $23.74 | EPS | $1.65 | |||
| Volume | 59,948,644 | |||||
